Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals Inc (XFOR) is a clinical-stage biopharmaceutical company pioneering oral therapies targeting the CXCR4 pathway to treat rare immunodeficiency disorders. This page provides a centralized hub for all official news, including press releases, clinical trial updates, and regulatory developments.
Investors and researchers will find timely updates on mavorixafor’s progress, partnership announcements, and financial disclosures. Content categories include clinical trial milestones, regulatory submissions, strategic collaborations, and earnings reports, ensuring comprehensive coverage of XFOR’s advancements.
Bookmark this page to stay informed about X4 Pharmaceuticals’ innovations in rare disease therapeutics, designed to address unmet medical needs through precision immunology.
X4 Pharmaceuticals (Nasdaq: XFOR) announced on October 30, 2020, that its Compensation Committee granted an inducement award under the 2019 Inducement Equity Incentive Plan to attract new employees. This grant consists of options to purchase 9,600 shares at an exercise price of $5.74 each, equal to the closing stock price on that date. The options will vest over four years, with 25% vesting after the first year. X4 focuses on developing therapies targeting CXCR4 dysfunction, with its lead candidate, mavorixafor, currently in Phase 3 trials for WHIM syndrome.
X4 Pharmaceuticals (Nasdaq: XFOR) has appointed Art Taveras, Ph.D., as its new Chief Scientific Officer. Dr. Taveras will lead research and non-clinical development for X4's pipeline, particularly the lead product candidate, mavorixafor, an oral therapy for rare genetic diseases. Dr. Taveras brings over 30 years of experience in small molecule drug discovery and has a strong background in chemokine-related chemistries. His leadership is expected to enhance X4's clinical programs and broaden its pipeline.
X4 Pharmaceuticals (Nasdaq: XFOR) will announce its third-quarter financial results on November 5, 2020. The company will provide updates on its business highlights during a conference call at 8:30 a.m. ET, accessible through U.S. and international dial-ins. X4 focuses on developing therapies targeting the CXCR4 pathway, with its lead candidate mavorixafor undergoing Phase 3 trials for WHIM syndrome and Phase 1b trials for other conditions. Interested parties can access the live webcast on the company’s investor relations page.
X4 Pharmaceuticals (Nasdaq: XFOR) announced that the FDA granted Fast Track Designation to its lead asset, mavorixafor, for treating WHIM syndrome, a rare genetic immunodeficiency disease. Mavorixafor is a first-in-class oral small molecule antagonist of the CXCR4 receptor, currently in a Phase 3 clinical trial. The Fast Track status will enable more frequent FDA meetings to discuss mavorixafor's development. Previous recognitions for mavorixafor include Breakthrough Therapy Designation and Orphan Drug status.
X4 Pharmaceuticals (Nasdaq: XFOR) announced the issuance of inducement equity awards to new employees under its 2019 Inducement Plan on September 30, 2020. These awards comprise options to purchase 30,500 shares of common stock at an exercise price of $6.77 per share, reflecting the closing price on that date. The options, which have a ten-year term, will vest over four years, contingent on the employees' ongoing employment. X4 develops therapies targeting the CXCR4 pathway, focusing on rare diseases, with its lead candidate, mavorixafor, currently in Phase 3 clinical trials.
X4 Pharmaceuticals (Nasdaq: XFOR) announced positive results from a Phase 2 study of mavorixafor, a potential treatment for WHIM syndrome, published in Blood. The study demonstrated that mavorixafor at 400 mg once daily improved white blood cell counts and significantly reduced infection rates and wart burden. The company aims to accelerate mavorixafor's development in a pivotal Phase 3 trial, anticipating results in 2022. These findings bolster the clinical strategy and validate the therapy's potential in a severely underserved patient population.
X4 Pharmaceuticals (Nasdaq: XFOR) announced on August 31, 2020, that its Compensation Committee issued inducement awards to new employees under the 2019 Inducement Plan. The awards consist of options to purchase 61,750 shares at an exercise price of $8.38, equal to the closing stock price on that date. These options have a ten-year term and will vest over four years. X4 Pharmaceuticals focuses on developing therapies for diseases linked to the CXCR4 pathway, with its leading candidate, mavorixafor, currently undergoing Phase 3 trials for WHIM syndrome.
X4 Pharmaceuticals (Nasdaq: XFOR) announced management will present and hold one-on-one meetings at the Virtual Canaccord Genuity 40th Annual Growth Conference on August 12, 2020, at 2:30 PM ET. A live webcast of the presentation will be accessible on the investor section of the X4 Pharmaceuticals website and archived for 90 days.
The firm specializes in therapies targeting CXCR4 pathway dysfunction, with its lead candidate, mavorixafor, being evaluated in multiple clinical trials for rare diseases and cancers.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) announced an inducement award of options to purchase 10,700 shares of its common stock to new employees under its 2019 Inducement Equity Incentive Plan. The options, set at an exercise price of $7.83 per share, will vest over four years, encouraging retention. This award aligns with Nasdaq Listing Rule 5635(c)(4). X4 is focused on therapies targeting CXCR4 pathway dysfunction, with its lead candidate, mavorixafor, undergoing various clinical trials.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) reported second-quarter 2020 financial results, revealing a net loss of $15.1 million, up from $13.4 million in Q2 2019. The company highlighted progress in its Phase 3 trial for WHIM syndrome, supported by positive Phase 2 data presented at EHA 2020, which indicated substantial disease prevalence estimates exceeding 3,500 cases in the U.S. Additionally, initial data from the Phase 1b trial in Waldenström’s macroglobulinemia is expected later this year. X4 holds $105.6 million in cash, expected to fund operations into early 2022.
